R149
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.530
- PROTEIN_SECRETION+0.530
- MTORC1_SIGNALING+0.420
- OXIDATIVE_PHOSPHORYLATION+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.380
- ADIPOGENESIS+0.370
- CHOLESTEROL_HOMEOSTASIS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- BILE_ACID_METABOLISM+0.330
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ANGIOGENESIS-0.350
- APICAL_JUNCTION-0.290
- HEDGEHOG_SIGNALING-0.290
- MYOGENESIS-0.290
- COAGULATION-0.270
- ESTROGEN_RESPONSE_EARLY-0.220
- HYPOXIA-0.220
- MITOTIC_SPINDLE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 131536 | EPN | EPN Tumor | 0.819 |
| 2 | SRR12696744 | — | — | 0.799 |
| 3 | TCGA-AR-A0TW-01A-11R-A084-07 | — | B | 0.797 |
| 4 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.795 |
| 5 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.794 |
| 6 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.792 |
| 7 | 20040027.LumB | — | C | 0.791 |
| 8 | 4769f22f-eeaf-4108-9555-55cc5d6ae27b | — | — | 0.790 |
| 9 | MNG510 | — | — | 0.789 |
| 10 | db087000-74fa-4044-812f-01842b99f448 | — | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |